Contraindications & Warnings
CONTRAINDICATIONS:
There are no contraindications for Dantrium® IV.
WARNINGS:
The use of Dantrium® Intravenous in the management of malignant hyperthermia crises is not a substitute for previously known supportive measures. These measures must be individualized, but it will usually be necessary to discontinue the suspect triggering agents, attend to increased oxygen requirements, manage the metabolic acidosis, institute cooling when necessary, monitor urinary output, and monitor for electrolyte imbalance.
Since the effect of disease state and other drugs on Dantrium® related skeletal muscle weakness, including possible respiratory depression, cannot be predicted, patients who receive i.v. Dantrium® preoperatively should have vital signs monitored.
If patients judged malignant hyperthermia susceptible are administered intravenous or oral Dantrium® preoperatively, anesthetic preparation must still follow a standard malignant hyperthermia susceptible regimen, including the avoidance of known triggering agents. Monitoring for early clinical and metabolic signs of malignant hyperthermia is indicated because attenuation of malignant hyperthermia, rather than prevention, is possible. These signs usually call for the administration of additional i.v. dantrolene.